6160 — BeOne Medicines AG Balance Sheet
0.000.00%
- HK$266.51bn
- HK$237.46bn
- CNY38.22bn
Annual balance sheet for BeOne Medicines AG, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 42,213 | 31,447 | 22,552 | 19,050 | 32,026 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3,529 | 1,433 | 3,224 | 5,266 | 6,265 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 48,541 | 36,174 | 29,810 | 28,907 | 43,622 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4,045 | 6,117 | 9,318 | 11,524 | 11,533 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 55,185 | 44,224 | 41,122 | 42,835 | 57,305 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10,204 | 10,303 | 12,833 | 16,004 | 12,587 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 15,259 | 13,893 | 16,018 | 18,659 | 26,666 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 39,926 | 30,331 | 25,103 | 24,175 | 30,639 |
| Total Liabilities & Shareholders' Equity | 55,185 | 44,224 | 41,122 | 42,835 | 57,305 |
| Total Common Shares Outstanding |